GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

GSK shares surge as the drugmaker raises its 2031 sales target to over £40bn, boosts dividends, and announces a £2bn share buyback plan.

Key Takeaways GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and ...

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

Real-time index price for TSX Diversified Banks EW Index (TXDE), along with buy or sell indicators, analysis, charts, ...

Chairman & CEO. “Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base PHILADELPHIA, October 24, 2024--New data for AREXVY, GSK’s RSV vaccine ...

Trump's tariffs could derail Europe's 2025 growth, say top Wall Street analysts. Goldman Sachs sees eurozone GDP at 0.7%, ...

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top ...

Former GSK CEO Sir Andrew Witty, and his former drug development chief, Moncef Slaoui have both lined up new jobs as life science investors. The announcements yesterday are part of a growing trend ...

The Mayor of London has launched a new nightlife taskforce which will be led by fabric nightclub founder Cameron Leslie - it will be advising on the future of nightlife in the capital ...

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...